Canopy Growth signs deal to sell its C3 Cannabinoid Compound Company GmbH subsidiary

  • 📰 globeandmail
  • ⏱ Reading Time:
  • 17 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 10%
  • Publisher: 92%

Sverige Nyheter Nyheter

Sverige Senaste nytt,Sverige Rubriker

Under the agreement, Canopy will receive an upfront payment of $115.5-million. The deal, which requires regulatory approvals, is expected to close by Jan. 31, 2022

says it has signed a deal to sell its C3 Cannabinoid Compound Company GmbH subsidiary to German company Dermapharm Holding SE.It will also receive up an additional $61.4-million, subject to the achievement of certain milestones by the business.

The business being sold develops and manufactures pharmaceutical products and includes Spectrum Therapeutics GmbH, THC Pharm GmbH The Health Concept and Spectrum Therapeutics Austria GmbH.Your time is valuable. Have the Top Business Headlines newsletter conveniently delivered to your inbox in the morning or evening.

 

Tack för din kommentar. Din kommentar kommer att publiceras efter att ha granskats.
Vi har sammanfattat den här nyheten så att du kan läsa den snabbt. Om du är intresserad av nyheterna kan du läsa hela texten här. Läs mer:

 /  🏆 5. in SE

Sverige Senaste nytt, Sverige Rubriker